Will you be able to get a COVID-19 shot? Here's what we know so far.
Until now, the U.S. — following guidance from independent experts who advise the Centers for Disease Control and Prevention — has recommended yearly COVID-19 vaccinations for everyone age 6 months and older.
Together, the moves have left health experts, vaccine makers and insurers uncertain about what to advise and what comes next.
Advertisement
'It's going to add a lot of confusion overall,' said Ajay Sethi, an epidemiologist at the University of Wisconsin, Madison.
How can I get a COVID-19 shot for myself or my healthy child?
Some of this season's vaccine is still available. Insurance industry experts say if people had insurance coverage before Kennedy's announcement, it's highly unlikely that would have ended instantly based on the secretary's video announcement. That means if someone could find a shot, they'd likely be able to get one for now.
Will I still be able to choose a shot in the fall for myself or my child?
Who will be able to get what vaccines this fall is still unclear.
Vaccine manufacturers plan to issue updated COVID-19 shots in the late summer or fall. But the Food and Drug Administration has said it plans to limit approval of seasonal shots to seniors and others at high risk, pending more studies of everyone else.
Advertisement
Even if the U.S. approves vaccines only for certain groups, it still may be possible for others to get the shot depending on the outcome of upcoming advisory meetings, regulatory moves and decisions from insurers and employers.
Will my insurance still pay?
Insurers base coverage decisions on the recommendations of that CDC panel, the Advisory Committee on Immunization Practices. It's not clear what role that panel now will play. Paying out of pocket could cost about $200.
But some insurers and employers may decide to still cover the shots regardless of the new recommendations, said Jen Kates, a senior vice president at the non-profit KFF, which studies health care issues. She noted that they may view the expense as worthwhile if it avoids a higher bill from someone hospitalized by the coronavirus.
What's considered increased risk?
The FDA published a list of health conditions it said would qualify, including asthma, cancer, diabetes, obesity and physical inactivity. The CDC has a more extensive list.
But, again, it isn't yet known how this will play out. For example, it could be hard for people to prove they're qualified. If they're vaccinated at a drugstore, for instance, the pharmacist wouldn't normally know about underlying health problems or even ask. Kates said it's unclear whether Kennedy's move would affect whether doctors recommend the shot.
And Sethi, the UW-Madison expert, said 'this elephant in the room' is that blocking vaccination to the healthy may mean people who have a risk factor and simply don't know it will miss out.
Adding to the confusion, the FDA included pregnancy and recent pregnancy on the list of conditions that would qualify someone for a shot — but Kennedy said that pregnancy was no longer a qualification in his announcement this week.
Advertisement
COVID-19 complications during pregnancy can include preterm birth as well as serious illness in the mother, and the Society for Maternal-Fetal Medicine said it 'strongly reaffirms' its recommendation for vaccination during pregnancy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
A new COVID subvariant spreads rapidly as Trump pivots away from vaccines
A new, highly transmissible COVID subvariant has been detected in California — heightening the risk of a potential summer wave as recent moves by the Trump administration threaten to make vaccines harder to get, and more expensive, for many Americans, some health experts warn. Health and Human Services Secretary Robert F. Kennedy Jr. announced this week that he was rescinding the federal government's recommendation that pregnant women and healthy children get immunized against COVID, effective immediately. Dr. Marty Makary, commissioner of the U.S. Food and Drug Administration, also said the agency will no longer routinely approve annually formulated COVID-19 vaccinations for healthy people under age 65. "We simply don't know whether a healthy 52-year-old woman with a normal BMI who has had COVID-19 three times and has received six previous doses of a COVID-19 vaccine will benefit from the seventh dose," Makary, along with another FDA official, Dr. Vinay Prasad, wrote in the New England Journal of Medicine this month. "This policy will compel much-needed evidence generation." Read more: Kennedy says COVID vaccines no longer recommended for healthy children and pregnant women However, some experts say mandating more extensive testing could delay vaccine access for many, as those efforts may not even be complete until after the end of the upcoming winter flu-and-COVID season. "Pregnant women, infants and young children are at higher risk of hospitalization from COVID, and the safety of the COVID vaccine has been widely demonstrated," Dr. Sean O'Leary, chair of the American Academy of Pediatrics' Committee on Infectious Diseases, said in a statement. The U.S. Centers for Disease Control and Prevention has said that, in general, getting an updated vaccine provides children and adults additional protection from COVID-related emergency room and urgent care visits. The recent federal changes, according to some experts, could also prompt private insurance companies and government insurers to stop paying for COVID shots for wide segments of the population, including babies and children. Absent a recommendation by federal officials, Americans could end up paying the entire cost of a vaccine, experts say. The out-of-pocket cost for a COVID vaccine at CVS, for instance, is $198.99. Read more: Trump administration cancels $766-million Moderna contract to fight pandemic flu Although the emergency phase of the pandemic has long since passed, authorities note COVID remains a public health concern. A relatively new subvariant has been spreading in Europe and Asia, "particularly Hong Kong, Taiwan, other countries, Japan, etc.," said Dr. Peter Chin-Hong, a UC San Francisco infectious diseases expert. That subvariant, NB.1.8.1, was first documented in January and has since been detected in California, including in Los Angeles County and the San Francisco Bay Area. The World Health Organization designated it a "Variant Under Monitoring" last week. NB.1.8.1 has grown exponentially worldwide in recent weeks. The Omicron subvariant represented 10.7% of genetically analyzed viral samples worldwide for the week ending April 27, WHO data show. That was up sharply from the week ending April 6, when the subvariant accounted for 2.5% of samples worldwide. "While still low numbers, this is a significant rise," the WHO said, adding that there was a "concurrent increase in cases and hospitalizations in some countries where NB.1.8.1 is widespread." Read more: Trump officials set new requirements for COVID vaccines in healthy adults and children NB.1.8.1 isn't yet prevalent enough in the United States to be publicly tracked by the CDC. Another strain, LP.8.1, accounted for an estimated 73% of coronavirus specimens nationally for the two-week period ending Saturday. Data suggest NB.1.8.1 does not cause more severe illness, "but it is more transmissible, at least from what we're seeing around the world and also from lab experiments," said Dr. Yvonne Maldonado, an infectious-disease expert at Stanford University. In Taiwan, a top health official told reporters that an NB.1.8.1-fueled outbreak was "continuing to rise rapidly, with a sustained increase in severe and fatal cases," the Central News Agency reported, prompting a shortage of COVID testing kits. Health officials said a factor in Taiwan's surge was the lack of a major COVID wave over the winter, and forecast that the island's current spike may not peak for another four to six weeks. NB.1.8.1 has seen increased prevalence in each of the three WHO regions that still consistently share genetic analysis of COVID samples — the Western Pacific (which includes East Asia, parts of Southeast Asia, and Australia); Europe; and the Americas. The rate at which COVID tests are coming back positive in Los Angeles County has slightly increased over the past few weeks, although the overall positive rate remains low, at 3.5%, according to the county Department of Public Health. Coronavirus levels detected in the county's wastewater have increased by 6% in the last three weeks, but also remain relatively low and are about one-eighth of the peak in the summer of last year. Read more: Ex-official says he was forced out of FDA after trying to protect vaccine safety data from RFK Jr. Although California experienced a mild winter season — a first of the COVID era — that followed a powerful summer spike that was the strongest in years. Many experts and officials have touted available COVID vaccines as effective both in warding off infection and in lessening the severity of symptoms. However, the need for otherwise healthy individuals to roll up their sleeves has been a matter of debate. In a video message Tuesday on X, Kennedy — a noted vaccine skeptic — said that he "couldn't be more pleased to announce that, as of today, the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC recommended immunization schedule." Experts said they could not recall a time when a political appointee circumvented a well-established process of making vaccine recommendations, which typically involves panels of scientists advising the FDA and CDC. "It's kind of chilling," Chin-Hong said. "It's out of step with the system we've learned to trust and follow." Read more: WHO adopts a 'pandemic agreement' after the chaos of COVID In a statement to The Times, the L.A. County Department of Public Health urged Kennedy to listen to experts in the field — including from the CDC's Advisory Committee on Immunization Practices, which is scheduled to meet next month — "before decreasing access to any vaccine." As of Thursday, the CDC still had the long-standing vaccine recommendations on its website: Everyone ages 6 months and older should get the most recent COVID-19 vaccine, officially known as the 2024-25 version, which was introduced in September. The CDC also recommends seniors ages 65 and up get a second vaccine dose six months after their first. In a statement, the California Department of Public Health said that it supports the current expansive recommendation for COVID vaccines, and that it "will continue to follow the federal conversation through this dynamic situation." "Staying up to date with COVID-19 vaccination can reduce the risk of disease, especially more severe cases that result in hospitalization or death," the department added. The Washington Post reported Wednesday that the CDC did not know of Kennedy's directive until he posted it, and officials have been "scrambling to find out what it meant." Experts who spoke with The Times warned the practical effect of the edict — if it becomes official — could be far more costly vaccines for affected groups. "If vaccines are not recommended by the CDC, insurance companies would NOT be required to cover the cost," the L.A. County Department of Public Health said in a statement. Read more: A pediatrician's dilemma: Should a practice kick out unvaccinated kids? As a result, the vaccines may be less accessible to healthier people who still want them — perhaps because they live or work with elderly or other higher-risk people, they've had severe COVID illness before, or they want to protect themselves against the latest subvariant, the agency said. If the FDA withholds a license for an updated COVID vaccination for younger, healthier adults, this group "would not be able to receive it unless their provider chooses to give it 'off label,'" the county said. When asked whether healthy pregnant women and healthy children can still get vaccinated at its pharmacies, Walgreens said its teams operate "in full compliance with applicable laws." CVS said its locations "follow federal guidance regarding vaccine administration and are monitoring any changes that the government may make regarding vaccine eligibility." Kaiser Permanente Southern California said it was aware of potential changes, but noted no new formal guidance has yet been issued. As a result, Kaiser is continuing to follow existing guidance, which recommends the shots for everyone. The L.A. County Department of Public Health said that as of Wednesday, "pregnant women and healthy children can get vaccinated for COVID-19," according to existing recommendations from an advisory panel and the CDC. Read more: RFK Jr. kept asking to see the science that vaccines were safe. After he saw it, he dismissed it Chin-Hong noted there were 150 pediatric deaths in the U.S. from COVID-19 in a recent one-year period. That's in the same ballpark as the 231 pediatric flu deaths recorded this season, and federal health officials recommend everyone ages 6 months and older get an annual flu shot. "Most people would agree that kids should be targeted for flu vaccines. It seems kind of weird to have COVID as an outlier in that respect," Chin-Hong said. In the video published this week, Makary said that "most countries in the world have stopped recommending the vaccine for children." Maldonado, however, said the U.S. doesn't use other nations' standards to dictate vaccine recommendations. The U.S., for instance, recommends other types of vaccines that have a lower prevalence than COVID that people want to get, Maldonado said, such as the meningococcal vaccine for children to guard against a serious bacterial disease that can infect the brain and spinal cord and cause death within hours. The effect of a recommendation also varies by country. Canada, for instance, recommends updated COVID vaccines for seniors and other people who meet certain criteria, such as if they're pregnant or are a healthcare worker. But the country's universal healthcare system still allows everyone ages 6 months and older to get an updated COVID vaccine. Although it's true that children overall are at lower risk of developing severe COVID illness, those under 6 months of age "have the same risk of complications as the 65-year-old-plus population in this country," said Stanford's Maldonado, who also serves on the CDC's Advisory Committee on Immunization Practices. Read more: Trump's first term brought world-changing vaccine. His second could bring retreat Among children eligible for vaccination, COVID-associated hospitalization rates are highest for those ages 6 months to 4 years, according to the CDC. "So are children going to be the highest risk group? No, they're not. But would you want to protect your child from a disease that could potentially put them in the hospital and get them on a ventilator? Yes, I would say that I would want to make that choice for myself. And why not allow the parent to make that choice?" Maldonado said. The CDC says COVID vaccination during pregnancy builds antibodies that can help protect the baby; studies have also shown that vaccinated moms who breastfeed have protective antibodies in their milk, which could help protect their babies. There have been an estimated 260,000 to 430,000 hospitalizations attributed to COVID since October, causing "an enormous burden on the healthcare system," Dr. Fiona Havers, a medical epidemiologist with the CDC, said at a recent public meeting. There have also been an estimated 30,000 to 50,000 COVID-19 deaths over the same time period. "It is a major cause of morbidity and mortality, particularly in older adults, but it does affect other people, particularly those with underlying conditions, in younger age groups." COVID is also a major cause of pediatric hospitalizations, even among otherwise healthy children, she said. "If there's a summer wave this year, we'll be seeing it in children being hospitalized with COVID as well," she said. Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week. This story originally appeared in Los Angeles Times.
Yahoo
27 minutes ago
- Yahoo
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
By Julie Steenhuysen and Deena Beasley (Reuters) -Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump Administration's pullback in aid spending. Some AIDS experts, including activists and doctors, say the Gilead drug, lenacapavir, could help end the 44-year-old epidemic that infects 1.3 million people a year and is estimated by the World Health Organization to have killed more than 42 million. An FDA approval decision is expected by June 19 for lenacapavir, which proved to be nearly 100% effective at preventing HIV in large trials. If the Food and Drug Administration green lights the drug, and its view is seconded by the WHO, the shots could start to roll out early in 2026 to at least 2 million people in 18 low-income countries based on Gilead's agreement with the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund, a worldwide partnership targeting HIV, tuberculosis and malaria. Gilead agreed to provide lenacapavir at cost for two-to-three years while six generic drugmakers, which were granted licenses to make the medicine for low-income countries, ramp up production. Experts said a successful launch of a long-acting HIV prevention drug could help stall the epidemic. Until recently, the only pre-exposure prophylaxis (PrEP) options for people at high risk of infection were daily pills, requiring careful adherence to be effective. "You can foresee a day where there are no new HIV diagnoses. It doesn't happen if we only do this in the U.S.," Gilead Chief Commercial Officer Johanna Mercier said. "We need to make sure we have a global approach to this launch." PEPFAR being part of the effort is Gilead's intent and goal, Mercier said. "Unfortunately, if they're not part of that mix, our goal is still to meet that objective of 2 million people getting access." Wall Street has a close eye on lenacapavir, one of the highest-profile drugs to undergo FDA review since President Donald Trump named Robert F. Kennedy Jr. as health secretary and promised to upend the status quo. Most of the drug's profits are expected in the U.S., with annual sales reaching $1 billion by next year, according to analysts' estimates compiled by LSEG. 'INCREDIBLE DISMAY' Whether all of the agreed funding for low-income countries - most of which are in Africa - will come through is unclear. Countries that rely on aid are already reeling from funding cuts by the Trump Administration, including to PEPFAR, and AIDS researchers are bracing for the worst. The United Nations program on HIV/AIDS earlier this month said many HIV prevention programs supported by PEPFAR were stalled, although services for pregnant and breastfeeding women were technically exempt from the cuts. Peter Sands, executive director of the Global Fund, told Reuters the group intends to fund as much of the lenacapavir rollout as possible, but it will need to start slowly. "It's not just the uncertainty over PEPFAR's funding that's an issue, but the uncertainty over our funding," Sands said, adding that the group's first priority is treating people already infected with the deadly virus. Much will depend on the success of the Global Fund's effort to raise $18 billion to fund its work from 2027-2029. The U.S. is its largest donor, committing $6 billion in the previous funding round. It is unclear what the U.S. may provide this round, or whether other big governments will step up. UNAIDS estimates that the permanent discontinuation of HIV prevention and treatment programs supported by PEPFAR would lead to an additional 6.6 million new HIV infections between 2025 and 2029. The U.S. State Department, which oversees PEPFAR, did not respond to a request for comment. Gilead declined to comment on its manufacturing cost for lenacapavir, whose U.S. price is likely to be on par with current preventive medications at around $25,000 per year. ViiV Healthcare's Apretude, an injection given every two months, costs about 124.20 pounds ($168) in low- and middle-income countries. Mitchell Warren, executive director of the AIDS nonprofit AVAC, estimates the eventual annual cost at $100-$120. The lower the price, the more people who could receive it, he said. Warren said PEPFAR could still participate, and others may come forward. The Gates Foundation and the Children's Investment Fund Foundation are "actively involved in all of these conversations," he said, as is the Elton John AIDS Foundation. Linda-Gail Bekker of the University of Cape Town, who led lenacapavir clinical trials in South Africa and Uganda, said she was elated when she first saw the findings. "The huge feeling I have now is one of incredible dismay," said Bekker of uncertainty over the Trump administration's commitment to PEPFAR and HIV prevention in poor nations. "It felt like the stars were aligning, and one of the stars has fallen out of the sky."
Yahoo
an hour ago
- Yahoo
Intellia stock dips following safety event in Phase III gene therapy trial
Intellia Therapeutics' stock has fallen nearly 23% following an announcement that a patient in its Phase III trial for a gene therapy targeting transthyretin amyloid (ATTR) cardiomyopathy suffered a serious adverse event (AE). In a filing by the Securities and Exchange Commission (SEC), the company reported that one patient experienced Grade 4 liver transaminase elevations after treatment with nexiguran ziclumeran (nex-z) in the Phase III MAGNITUDE trial (NCT06128629). According to Intellia, the event is resolving without the need for hospitalisation or medical intervention. Upon the announcement, Intellia's stock, listed on the Nasdaq exchange, dropped by 22.87% from $9.66 a share at market close on 28 May to $7.45 at market close on 29 May. Intellia emphasised that this is a single event from more than 200 patients dosed with nex-z in the MAGNITUDE study. Other AEs have been similar to those seen in the Phase I study, including infusion-related reactions and asymptomatic liver transaminase elevations. The SEC filing added that Intellia said it will continue to monitor these events as the study progresses. The trial has so far enrolled 365 patients out of an expected total enrollment of approximately 765 patients, which Intellia says is on track. The company aims to complete enrollment by early 2027. Intellia is also investigating nex-z in the Phase III MAGNITUDE-2 study (NCT06672237), which is enrolling patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Dosing has started, with investigators seeking data on whether the therapy will lead to a reduction in serum TTR. Intellia will be waiting for data from MAGNITUDE-2 before filing a biologics licence application (BLA) to the US Food and Drug Administration (FDA) in 2028, with hopes for a 2029 commercial launch. It has been a challenging time for gene therapy development, with several severe AEs and, in some instances, fatalities seeming to plague investors' views on the therapeutic approach. On 27 May, Rocket Pharmaceuticals announced that a patient died in its Phase II trial for a Danon disease gene therapy after suffering a serious AE. In March 2025, Sarepta and Roche reported the death of a teenage patient dosed with its AAV gene therapy for Duchenne muscular dystrophy (DMD), Elevidys (delandistrogene moxeparvovec-rokl), causing agencies to pause ongoing clinical studies. This pause has since been lifted. Last year, a fatality in Pfizer's Phase II DMD gene therapy trial, as well as low efficacy in a Phase III study, caused the big pharma to drop the development of the AAV candidate, named fordadistrogene movaparvovec. Earlier this month, the FDA shared that American haematologist oncologist Vinay Prasad will lead its Center for Biologics Evaluation and Research (CBER), the division responsible for regulating gene therapies and vaccines. Prasad has openly criticised Elevidys, primarily about the clinical evidence and the FDA's decision to approve the therapy, which raises questions about his overall opinion of the gene therapy approach. "Intellia stock dips following safety event in Phase III gene therapy trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
